J. Hartke

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

John T. Chang, Siddharth Singh, B. Sands, 2018, Gastroenterology.

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Siddharth Singh, B. Sands, C. Siegel, 2018, The American Journal of Gastroenterology.

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

Siddharth Singh, B. Sands, C. Siegel, 2018, Inflammatory bowel diseases.

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.

Siddharth Singh, B. Sands, C. Siegel, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium

Siddharth Singh, B. Sands, C. Siegel, 2017 .

DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium.

B. Sands, C. Siegel, W. Sandborn, 2017, Journal of Crohn's & colitis.

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Siddharth Singh, B. Sands, C. Siegel, 2018, The American Journal of Gastroenterology.